Comparative antiproliferative effects of 111In-DTPA-hEGF, chemotherapeutic agents and γ-radiation on EGFR-positive breast cancer cells

Nuclear Medicine and Biology

Volumn 29, Issue 6, 2002, Pages 693-699

  Chen, Paul ^a   Mrkobrada, Marko ^c   Vallis, Katherine A ^a,c   Cameron, Ross ^a   Sandhu, Jasbir ^b   Hendler, Aaron ^a,c   Reilly, Raymond M ^a,c,d  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b MOUNT SINAI HOSPITAL   (United States)

^c UNIVERSITY OF TORONTO   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

Author keywords

radiation; Breast cancer; Chemotherapy; Epidermal growth factor; Epidermal growth factor receptor; Indium 111

Indexed keywords

ANTINEOPLASTIC AGENT; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; FLUOROURACIL; METHOTREXATE; PACLITAXEL; PENTETIC ACID EPIDERMAL GROWTH FACTOR IN 111; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; CANCER GROWTH; CANCER INHIBITION; CELL CULTURE; CELL LEVEL; CELL PROLIFERATION; CHEMOTHERAPY; CONTROLLED STUDY; DRUG EFFECT; GAMMA RADIATION; HUMAN; HUMAN CELL; IC 50; INTERMETHOD COMPARISON; RADIATION DOSE; RADIATION RESPONSE;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; DOXORUBICIN; EPIDERMAL GROWTH FACTOR; GAMMA RAYS; HUMANS; METHOTREXATE; PENTETIC ACID; RADIOPHARMACEUTICALS; RECEPTOR, EPIDERMAL GROWTH FACTOR; TREATMENT OUTCOME; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL;

EID: 0036701613     PISSN: 09698051     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0969-8051(02)00325-6     Document Type: Article

References (25)

1. Armstrong D.K., Kaufmann S.H., Ottaviano Y.L., Furuya Y., Buckley J.A., Isaacs J.T., Davidson N.E. Epidermal growth factor-mediated apoptosis of MDA-MB-468 human breast cancer cells. Cancer Res. 54:1994;5280-5283.
2. Balaban E.P., Simon T.R., Frenkel E.P. Toxicity of indium-111 on the radiolabeled lymphocyte. J Nucl Med. 28:1987;229-233.
3. 111In-hEGF against MDA-MB-468 human breast cancer xenografts is tumor-size dependent. J Nucl Med. 45:2001;255P.
4. y humanized 3S193 radioimmunotherapy in a breast cancer model enhanced activity when combined with taxol . Clin Cancer Res. 6:2000;3621-3628.
5. DeNardo S.J., Kukis D.L., Kroger L.A., O'Donnell R.T., Lamborn K.R., Miers L.A., DeNardo D.G., Meares C.F., Denardo G.L. Synergy of taxol and radioimmunotherapy with yttrium-90-labeled chimeric L6 antibody efficacy and toxicity in breast cancer xenografts . Proc Natl Acad Sci USA. 94:1997;4000-4004.
6. Fields Jones S.M., Burris H.A. III. Breast cancer. Herfindal E.T., Gourley D.R., Textbook of Therapeutics Drug and Disease Management . 1996;1533-1547 Williams & Wilkins, Baltimore, MD.
7. Filmus J., Polak M.N., Cailleau R., Buick R.N. A human breast cancer cell line with a high number of epidermal growth factor (EGF) receptors, has an amplified EGF receptor gene and is growth inhibited by EGF. Biochem Biophys Res Commun. 128:1985;898-905.
8. Filmus J., Trent J.M., Pollak M.N., Buick R.N. Epidermal growth factor receptor gene-amplified MDA-468 breast cancer cell line and its non-amplified variants. Molec Cell Biol. 7:1987;251-257.
9. Goddu S.M., Howell R.W., Rao R.D.V. Cellular dosimetry absorbed dose fractions for monoenergetic electron and alpha particle sources and S-values for radionuclides uniformly distributed in different cell compartments . J Nucl Med. 35:1994;303-316.
10. Goldhirsch A., Francis P., Castiglione-Gertsch M., Gelber R.D., Coates A.S. Taxanes as adjuvant for breast cancer. } Lancet. 356:2000;507-508.
11. Hofer K.G., Harris C.R., Smith M.J. Radiotoxicity of intracellular Ga-67, I-125 and H-3. Nuclear versus cytoplasmic radiation effects in murine L1210 leukemia cells. Int J Radiat Biol Rel Stud Phys Chem Med. 28:1975;225-241.
12. Hu W.W., Long G.D., Stockerl-Goldstein K.E., Johnston L.J., Chao N.J., Negrin R.S., Blume K.G. A feasibility study of multiple cycle therapy with melphalan, thiotepa, and paclitaxel followed by mitoxantrone, thiotepa, and paclitaxel with autologous hematopoietic cell support for metastatic breast cancer. Clin Cancer Res. 5:1999;3411-3418.
13. 111In-labeled oligodeoxyribonucleotides. J Nucl Med. 41:2000;1093-1101.
14. Klijn J.G.M., Berns P.M.J.J., Schmitz P.I.M., Foekens J.A. The clinical significance of epidermal growth factor receptor (EGF-R) in human breast cancer a review on 5232 patients . Endocr Rev. 13:1992;3-17.
15. 1]-octreotide. A case history. Ann NY Acad Sci. 733:1994;496-506.
16. Krenning E.P., Valkema R., Kooij P.P.M., Breeman W.A.P., Bakker W.H., deHerder W.W., van Eijck C.H.J., Kwekkeboom D.J., deJong M., Pauwels S. Peptide receptor radionuclide therapy with [indium 111 DTPA D Phe] octreotide. J Nucl Med. 38:(Suppl.):1997;47.
17. Mariani G., Bodei L., Adelstein S.J., Kassis A.I. Emerging roles for radiometabolic therapy of tumors based on Auger electron emission. J Nucl Med. 41:2000;1519-1521.
18. McCloskey D.E., Kaufmann S.H., Prestigiacomo L.J., Davidson N.E. Paclitaxel induces programmed cell death in MDA-MB-468 human breast cancer cells. Clin Cancer Res. 2:1996;847-854.
19. Moore M.J., Erlichman C. Pharmacology of anticancer drugs. Tannock I.F., Hill R.P., The Basic Science of Oncology. 3rd Ed. 1998;370-391 McGraw Hill, Toronto.
20. Reilly R.M., Sandhu J.S., Alvarez-Diez T., Gallinger S., Kirsh J., Stern H.S. Problems of delivery of monoclonal antibodies Pharmaceutical and pharmacokinetic solutions . Clin Pharmacokinet. 28:1995;126-142.
21. Reilly R.M., Kiarash R., Sandhu J., Lee Y.W., Cameron R., Hendler A., Vallis K., Gariépy J. A comparison of epidermal growth factor and monoclonal antibody 528 labeled with indium-111 for imaging human breast cancer. J Nucl Med. 41:2000;903-911.
22. Reilly R.M., Kiarash R., Cameron R., Porlier N., Sandhu J., Hill R.P., Vallis K., Hendler A., Gariépy J. Indium-111 labeled EGF is selectively radiotoxic to human breast cancer cells overexpressing EGFR. J Nucl Med. 41:2000;429-438.
23. Thomas T., Balabhadrapathruni S., Gardner C.R., Hong J., Faaland C.A., Thomas T.J. Effects of epidermal growth factor on MDA-MB-468 breast cancer cells alterations in polyamine biosynthesis and the expression of p21/CIP1/WAF1 . J Cell Physiol. 179:1999;257-266.
24. Wang J., Chen P., Su Z.-F., Vallis K., Sandhu J., Cameron R., Hendler A., Reilly R.M. Amplified delivery of indium-111 to EGFR-positive human breast cancer cells. Nucl Med Biol. 28:2001;895-902.
25. Zimmerman T.M., Grinblatt D.L., Malloy R., Williams S.F. A phase I dose escalation trial of continuous infusion paclitaxel to augment high dose cyclophosphamide and thiotepa plus stem cell rescue for the treatment of patients with advanced breast carcinoma. Cancer. 83:1998;. 1540-154.